Hohneker John

SEC source: 0001108205-26-000094 · wk-form4_1783627918.xml · derivative · entry 1

Hohneker John · CIK 0001695378 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,800

Underlying: Common Stock · 6,800 shares

Expires 2036-07-06

F1 · derivative.exercise_date: The option grant described in this Form 4 filing vests as to 100% of the underlying shares on July 7, 2027.

SEC source: 0001104659-26-076567 · tm2618519-2_4seq1.xml · derivative · entry 1

Hohneker John · CIK 0001695378 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,562

Underlying: Common Stock · 13,562 shares

Expires 2036-06-17

F1 · derivative.exercise_date: The shares underlying this option vest on the first anniversary of the grant date, subject to the Reporting Person's continued service through the applicable vesting date.

SEC source: 0001104659-25-061268 · tm2518583-2_4seq1.xml · derivative · entry 1

Hohneker John · CIK 0001695378 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,502

Underlying: Common Stock · 15,502 shares

Expires 2035-06-17

SEC source: 0001108205-25-000068 · wk-form4_1747944814.xml · derivative · entry 1

Hohneker John · CIK 0001695378 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,400

Underlying: Common Stock · 14,400 shares

Expires 2035-01-27

F1 · date: This option grant, as disclosed in Curis Inc.'s 2025 proxy statement, was approved by the Board of Directors of Curis, Inc. on January 28, 2025, contingent upon shareholder approval of Curis's Amendment No. 1 to the Fifth Amended and Restated 2010 Stock Incentive Plan to increase the number of shares authorized for issuance thereunder; and further provided that such option would not be exercisable and no common stock would be issued thereunder, if Amendment No. 1 to the Fifth Amended and Restated 2010 Plan was not approved by Curis's shareholders. On May 20, 2025, at the 2025 annual meeting of shareholders, Curis's shareholders approved Amendment No. 1 to the Fifth Amended and Restated 2010 Plan.

F2 · derivative.exercise_date: The option grant described in this Form 4 filing vests as to 100% of the underlying shares on January 28, 2026.

SEC source: 0001108205-25-000006 · wk-form4_1738271021.xml · derivative · entry 1

Hohneker John · CIK 0001695378 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,600

Underlying: Common Stock · 1,600 shares

Expires 2035-01-27

F1 · derivative.exercise_date: The option grant described in this Form 4 filing vests as to 100% of the underlying shares on January 28, 2026.

SEC source: 0001104659-24-075717 · tm2418415-1_4seq1.xml · derivative · entry 1

Hohneker John · CIK 0001695378 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,350

Underlying: Common Stock · 19,350 shares

Expires 2034-06-26

F1 · derivative.exercise_date: The shares underlying this option vest with respect to all of the shares underlying such option on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to the non-employee director's continued service as a director.

SEC source: 0001108205-24-000049 · wk-form4_1716494885.xml · derivative · entry 1

Hohneker John · CIK 0001695378 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,250

Underlying: Common Stock · 4,250 shares

Expires 2034-01-19

F1 · date: This option grant, as disclosed in Curis Inc.'s 2024 proxy statement, was approved by the Board of Directors of Curis, Inc. on January 20, 2024, contingent upon shareholder approval of Curis's Fifth Amended and Restated 2010 Stock Incentive Plan to increase the number of shares authorized for issuance thereunder; and further provided that such option would not be exercisable and no common stock would be issued thereunder, if the Fifth Amended and Restated 2010 Plan was not approved by Curis's shareholders. On May 21, 2024, at the 2024 annual meeting of shareholders, Curis's shareholders approved the Fifth Amended and Restated 2010 Plan.

F2 · derivative.exercise_date: The option grant described in this Form 4 filing vests as to 100% of the underlying shares on January 20, 2025.

SEC source: 0001104659-24-063518 · tm2414893-2_4seq1.xml · derivative · entry 1

Hohneker John · CIK 0001695378 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 29,550

Underlying: Common Stock · 29,550 shares

Expires 2034-05-15

F1 · derivative.exercise_date: These options vest annually in equal installments over three years, subject to the Reporting Person's continued service through the applicable vesting date.

SEC source: 0001104659-24-042053 · tm2410345-2_4seq1.xml · derivative · entry 1

Hohneker John · CIK 0001695378 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 38,700

Underlying: Common Stock · 38,700 shares

Expires 2034-04-01

F1 · derivative.exercise_date: The shares underlying this option vest over three years in equal monthly installments following April 1, 2024, subject to continued service to Carisma Therapeutics Inc. through the applicable vesting date.

SEC source: 0001694665-23-000087 · wk-form4_1686600399.xml · derivative · entry 1

Hohneker John · CIK 0001695378 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2033-06-08

F1 · derivative.exercise_date: The option vests on the earlier of June 8, 2024, and the day immediately prior to the date of the next annual meeting of the Issuer's stockholders occurring after the date of the grant.

SEC source: 0001108205-23-000015 · wf-form4_167459490789291.xml · derivative · entry 1

Hohneker John · CIK 0001695378 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 85,000

Underlying: Common Stock · 85,000 shares

Expires 2033-01-22

F1 · derivative.exercise_date: Options granted under the 2010 Amended and Restated Stock Incentive Plan and will vest as to 100% of the underlying shares on the first anniversary of the date of grant (January 23, 2024), subject to the director's continued service with the Company.

SEC source: 0001437749-22-023055 · rdgdoc.xml · derivative · entry 1

Hohneker John · CIK 0001695378 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 97,063

Underlying: Common Stock · 97,063 shares

Expires 2032-09-22

F1 · derivative.exercise_date: These options vest pro rata on a monthly basis commencing on October 23,2022 for the next 12 months with full vesting, if not fully vested at such time, on the date of Aravive, Inc.'s next annual meeting of stockholders.

SEC source: 0001214659-22-009392 · marketforms-56760.xml · derivative · entry 1

Hohneker John · CIK 0001695378 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 63,195

Underlying: Common Stock · 63,195 shares

Expires 2032-07-26

F1 · derivative.exercise_date: The stock option vests in two equal installments on the first and second anniversaries of the grant date.

SEC source: 0001694665-22-000102 · wf-form4_165515304223207.xml · derivative · entry 1

Hohneker John · CIK 0001695378 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2032-06-09

F1 · derivative.exercise_date: The option vests on the earlier of June 9, 2023 and the day immediately prior to the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant.

SEC source: 0001209191-22-005686 · doc4.xml · derivative · entry 1

Hohneker John · CIK 0001695378 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 85,000

Underlying: Common stock · 85,000 shares

Expires 2032-01-30

F1 · derivative.exercise_date: Options granted under the 2010 Amended and Restated Stock Incentive Plan and will vest as to 100% of the underlying shares on the first anniversary of the date of grant (January 31, 2023), subject to the director's continued service with the Company.

SEC source: 0001214659-22-000273 · marketforms-54944.xml · derivative · entry 1

Hohneker John · CIK 0001695378 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,538

Underlying: Common Stock · 3,538 shares

Expires 2031-12-30

F1 · price: The stock option was granted to Mr. Hohneker in lieu of $10,054 of cash compensation otherwise payable to Mr. Hohneker in respect of his services as a director during the fourth quarter of 2021.

F1 · derivative.exercise_date: The stock option was granted to Mr. Hohneker in lieu of $10,054 of cash compensation otherwise payable to Mr. Hohneker in respect of his services as a director during the fourth quarter of 2021.

SEC source: 0001209191-21-068030 · doc4.xml · derivative · entry 1

Hohneker John · CIK 0001695378 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common stock · 25,000 shares

Expires 2031-12-01

F1 · derivative.exercise_price: Options granted under the Fourth Amended and Restated 2010 Stock Incentive Plan and will vest over a period of four years with 25% of the shares underlying the stock option vesting on December 2, 2022, and an additional 6.25% of the shares vesting at the end of each successive three-month period thereafter until the options are fully vested on December 2, 2025, subject to Dr. Hohneker's continued service on the Company's Board.

F1 · derivative.exercise_date: Options granted under the Fourth Amended and Restated 2010 Stock Incentive Plan and will vest over a period of four years with 25% of the shares underlying the stock option vesting on December 2, 2022, and an additional 6.25% of the shares vesting at the end of each successive three-month period thereafter until the options are fully vested on December 2, 2025, subject to Dr. Hohneker's continued service on the Company's Board.

SEC source: 0001214659-21-010653 · marketforms-54041.xml · derivative · entry 1

Hohneker John · CIK 0001695378 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,866

Underlying: Common Stock · 42,866 shares

Expires 2031-10-18

F1 · derivative.exercise_date: The option vests in 12 ratable quarterly installments commencing March 31, 2022.

SEC source: 0001437749-21-022013 · rdgdoc.xml · derivative · entry 1

Hohneker John · CIK 0001695378 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,812

Underlying: Common Stock · 22,812 shares

Expires 2031-09-09

F1 · derivative.exercise_date: These options vest pro rata on a monthly basis commencing on October 10, 2021 for the next 12 months with full vesting, if not fully vested at such time, on the date of Aravive, Inc.'s next annual meeting of stockholders.

SEC source: 0001437749-21-016341 · rdgdoc.xml · derivative · entry 2

Hohneker John · CIK 0001695378 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,245

Underlying: Common Stock · 5,245 shares

Expires 2031-06-30

F2 · shares: Consists of options to purchase 5,245 shares of the Corporation's common stock, with immediate vesting as to 2,623 shares and 2,622 shares vesting on a monthly basis over two (2) months commencing on the one-month anniversary of the grant date with full vesting, if not fully vested at such time, on the date of the Corporation's next annual meeting of stockholders

SEC source: 0001437749-21-016341 · rdgdoc.xml · derivative · entry 1

Hohneker John · CIK 0001695378 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,435

Underlying: Common Stock · 15,435 shares

Expires 2031-06-30

F1 · shares: Consists of options to purchase 15,435 shares of the Corporation's common stock, with immediate vesting as to 858 shares and 14,577 shares vesting pro rata over 34 months commencing on the one-month anniversary of the date of grant.

SEC source: 0001694665-21-000025 · wf-form4_161195957616497.xml · derivative · entry 1

Hohneker John · CIK 0001695378 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,380

Underlying: Common Stock · 31,380 shares

Expires 2031-01-27

F1 · derivative.exercise_date: The option vests in thirty-six (36) substantially equal monthly installments over three years following the grant date, subject to continued service on the Board through each such vesting date.

SEC source: 0001209191-17-059627 · doc4.xml · derivative · entry 1

Hohneker John · CIK 0001695378 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 38,000 shares

Expires 2027-01-17

F1 · price: This stock option, which vests annually over three years, beginning January 18, 2017, subject to the director's continued service on the Board, was assumed by Ultragenyx Pharmaceutical Inc. ("Ultragenyx"), and converted in accordance with the exchange ratio as set forth in the Agreement and Plan of Merger (the "Merger Agreement"), dated October 2, 2017, between the Issuer, Ultragenyx and Mystic River Merger Sub Inc., a direct, wholly-owned subsidiary of Ultragenyx.

F1 · derivative.exercise_date: This stock option, which vests annually over three years, beginning January 18, 2017, subject to the director's continued service on the Board, was assumed by Ultragenyx Pharmaceutical Inc. ("Ultragenyx"), and converted in accordance with the exchange ratio as set forth in the Agreement and Plan of Merger (the "Merger Agreement"), dated October 2, 2017, between the Issuer, Ultragenyx and Mystic River Merger Sub Inc., a direct, wholly-owned subsidiary of Ultragenyx.

SEC source: 0001209191-17-004976 · doc4.xml · derivative · entry 1

Hohneker John · CIK 0001695378 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38,000

Underlying: Common Stock · 38,000 shares

Expires 2027-01-17

F1 · derivative.exercise_date: This stock option vests annually over three years, beginning on January 18, 2017, subject to the director's continued service on the Board.